KLSE (MYR): HARTA (5168)
You're accessing 15 mins delay data. Turn on live stream now to enjoy real-time data!
Last Price
2.99
Today's Change
+0.08 (2.75%)
Day's Change
2.90 - 3.04
Trading Volume
6,618,600
A price target is an analyst's projection of a share's future price.
Average Target Price, Price Call and Upside/Downside here are derived from Price Targets in the past 6 months.
Last Price
2.99
Avg Target Price
3.02
Upside/Downside
+0.03 (1.00%)Price Call
10
SELL
8
HOLD
27
BUY
Date | Open Price | Target Price | Upside/Downside | Price Call | Firm | View | Action |
---|
i've been wondering the same thing too. reputation's at stake plus share price plunged by 10%++, no reaction at all?
2 weeks ago
After reading the pusing article, I leave the 'subsidiary' part open to question. I did some Googling and couldn't find prove of it. So I guess I was wrong.
Huangbk72
@Chipee
U should read the article carefully.
Mun Health is a subsidiary of Hartalega
Sslee
Name of company Country of incorporation Principal activities Proportion of ownership interests and voting rights held by the Group
2024 2023
Subsidiaries of Hartalega Sdn. Bhd.
MUN Health Product (India) Pvt Ltd (1) India Retail and wholesale of gloves 81% 81%
2 weeks ago
Harta never expose themselves much in India market folks, their main market is in other region haha weak retailers pls sell
2 weeks ago
Another day, another tin kosong comment from him. 😂
NatsukoMishima
EU n USA will follow India to ban also !
2 weeks ago
"In view of the Honourable High Court's findings of the breaches by the defendant of Section 317A of the Capital Markets and Services Act 2007, Section 213 and Section 218 of the Companies Act 2016, the company shall consult its solicitors on the next course of action in relation to lodging complaints to the SC and to SSM respectively," it said.
Hartalega and two of its subsidiaries, Hartalega Sdn Bhd and Mun Health Product (India) Pvt Ltd, filed the civil suit against Danaraj in Dec 30, 2020, alleging that he set up a competing business using Mun Health Product's resources during his tenure with Hartalega.
According to Hartalega's 2019 annual report, Danaraj, held the position of executive director from July 4, 2011 until July 1, 2020.
He was in charge of the subsidiaries in China and India, where he was also an equity partner.
1 week ago
Hard to see robust np due to ringgit skyrocket ! Headwind for malaysia glove stock ! Not a good timing !
1 week ago
Topglove highlight
1. The Group is optimistic that the strong growth momentum will sustain, as customers continue replenishing their depleting glove stockpiles. The group continues to see MoM uptrend in sales volume in Sept 2024 and expects customers’ replenishment activity to pick up in subsequent quarters, underpinned by inventory rebuilding by distributors, indicating that demand recovery had further gained momentum. Presently, its sales volume had strengthened 25%-30% MoM, bringing utilisation rate to 65%-70% vs. our assumption of 55% in FY25 (based on 64b pieces capacity) compared to 45% in 3QFY24. Recall, it has previously highlighted that the bulk of a shipment delay in 3QFY24 estimated at 500m pieces had already been shipped and will be booked in 4QFY24.
2. It is optimistic that ASPs are expected to inch up gradually, potentially by 5%-15% or USD0.80 - USD1.50 per 1,000 pieces due to the uptick in demand and mitigation against the appreciating MYR against USD. However, due to the lag impact, ASP increases will only be felt gradually starting from Nov-Dec CY24. We believe predatory pricing by certain overseas players (i.e. selling below cost over an extended period to eliminate competition) have diminished as Chinese players’ utilization hit >90% While TOPGLOV is silent on existing ASP, we estimate every USD1 change impacts earnings by below 2%. We conservatively assumed ASP of USD20/1,000 pieces in our earnings model.
3. The group highlight that its exports to the US is continuing to show improvement which currently accounts for 28%-30% of its geographical sales mix. As an indication, TOPGLOV has seen its volume sales from the US market raising 20% YoY to account for 15% in 9MFY24 compared to pre-pandemic average of 20%-30%.
1 week ago
FBMKLCI Shake-Up in Q3: Sector WINNERS and LOSERS - YTLPOWER, MAYBANK, YTL, HARTA, TOPGLOV, CIMB, GAMUDA
https://klse.i3investor.com/web/blog/detail/bestStocks/2024-09-29-story-h470135190-FBMKLCI_Shake_Up_in_Q3_Sector_WINNERS_and_LOSERS
1 week ago
I'm starting to believe that this is just adjustment to the knee jerk reaction when US announced tariff increase effective 2025. Also on surface the ringgit strengthening will have some impact since Harta exports to US quite a bit, but hopefully there's some positive to be taken by being able to price the products more competitively.
As usual, we can only wait and see, and trust the management.
I just hope they can say something about MUN Health, unless they can't due to legal issues that could still be ongoing in the background.
1 week ago
‘No challenges can stop China’s progress’ Xi Jinping says in 75th anniversary speech
1 week ago
xD once a joker, forever a joker.
As far as I'm concerned, Harta is 100% up from its 3 year low when you keep singing the "Penny stock" song.
And Dnex is still stuck below 40c. This is called KARMA. You deserve every bit of it. And I'm enjoying ALL of it. xDDD
1 week ago
healthcare services are often considered defensive, increase volume sold, plant utilisation and ASP hike are main catalyst to propel earning recovery back to prepademic earning.
1 week ago
The chlorinated gloves news in India pop up as soon as the court case came up with the verdict and after the recent AGM...surely there should be lots of queries on the matter instead of just a couple during this last AGM related to these subsidiaries. As there will be further follow up on the verdict, will just wait for the response on the matter, if there is any, in the coming days.
1 week ago
Bargain Hartalega & Kossan
Hartalega will need convincing strength above the 100-day ma (RM3.06) to fuel further upside towards RM3.30, the 123.6%FP (RM3.43) and 138.2%FP (RM3.68) ahead, while downside risk is capped by the 76.4%FR (RM2.66). Kossan need a confirmed breakout above the 200-day ma (RM2.06) to enhance upside momentum towards the 100-day ma (RM2.19), RM2.33 and 123.6%FP (RM2.42) going forward, while the 61.8%FR (RM1.79) and lower Bollinger band (RM1.71) cushions downside.
1 week ago
It's still the same price as 2 days ago. Confirm Nutsucker like to chase high and kena cut. Siapa yang makan cili, dia yang rasa pedas.
1 week ago
Not only buy high, but also sell low. xD I think they bought dnex at around RM1. hahahahahhaha
1 week ago
xD Natsuko sharing his secret - buy high sell low. But unfortunately its hard to execute that in this counter, last week someone waiting for 2.4 until now also belum datang. Your penny stock prediction also wait 2 years belum datang, slowly wait la har you all.
1 week ago
reality, deep in their heart , many very happy when others lost money, when others made monies , they congratulate them with envy feeling.
1 week ago
Indications are pointing to a strong demand recovery moving into 4QCY24 and CY25 that will exceed our previous assumptions, underpinned by inventory rebuilding from distributors. Specifically, there has been uptick in orders over the past two quarters. The rise in demand comes as the inventories of major distributors across all regions have returned to normal levels. Case in point - HARTA expects to hit sales volume of 2.2b pieces/month in 2HFY25. Already, HARTA has seen 1QFY25 orders hitting close to 2b pieces per month compared to 1.5b-1.8b pieces per month in 4QFY24 and 3QFY23. TOPGLOV is optimistic that the strong growth momentum will sustain, as customers continue replenishing their depleting glove stockpiles. The group continues to see MoM uptrend in sales volume in June 2024 and expect customers’ replenishment activity to pick up in subsequent quarters, underpinned by inventory rebuilding from distributors, indicating early signs of potential recovery in demand. It has seen sales order rising 25%-30% MoM. Tell-tale signs of predatory pricing by certain overseas players (i.e. selling below cost over an extended period of time to eliminate competitors) have diminished. Specifically, glove players under our coverage have seen their ASPs rising over the past two quarters, potentially implying demand is on the path to a recovery boosted by order replenishment.
1 week ago
What a surprise. Kenanga has changed his views about the glove industry
https://klse.i3investor.com/web/pricetarget/research/72794
1 week ago
USD strength further to RM 4.27 due to global tension and fed hint no rush to cut rate
4 days ago
Malaysia’s gloves export volume surged 66% MoM and 105% YoY in Aug, outpacing the growth in July (+12% MoM; +43% YoY). The latest export volume is even 34% higher compare to pre-pandemic 2-years monthly average number indicating that the recovery momentum of global gloves demand remains healthy.
4 days ago
Disappear d the Mr. 2.4, I think they trying to invent time travel machine to go back last month to buy at 2.4. hahahahhahahah
1 day ago
I think we can forget about Q3 result. Look at Topglove, they make a loss and the stock is up.
Bull all the way for gloves.
16 hours ago
LittleKnife
no comment from harta ? It's been 3 days already
2 weeks ago